Source Post
The creator highlights Nasus Pharma (NSRX) and its proprietary intranasal drug delivery platform, focusing...
Sep 29, 2026
The creator highlights Nasus Pharma (NSRX) and its proprietary intranasal drug delivery platform, focusing on its lead candidate NS002 for anaphylaxis and its potential to improve upon traditional injectable treatments.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.